Renal denervation for the management of resistant hypertension

Integrated Blood Pressure Control

Volumn 8, Issue , 2015, Pages 57-69

  Patel, Hitesh C ^a   Hayward, Carl ^a   Vassiliou, Vassilis ^a   Patel, Ketna ^b   Howard, James P ^c   Di Mario, Carlo ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Renal denervation; Resistant hypertension; Simplicity; Sympathetic nervous system

Indexed keywords

NORADRENALIN; SPIRONOLACTONE;

ADRENERGIC SYSTEM; ARTERY DISSECTION; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL EFFECTIVENESS; EFFERENT NERVE; FALSE ANEURYSM; FEMORAL ARTERY; FOLLOW UP; HEMATOMA; HUMAN; KIDNEY ARTERY; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; KIDNEY DENERVATION SYSTEM; KIDNEY DISEASE; KIDNEY NERVE; META ANALYSIS (TOPIC); NEUROANATOMY; NONHUMAN; RADIOFREQUENCY RADIATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINNERVATION; RENAL SYMPATHECTOMY; RESISTANT HYPERTENSION; REVIEW; SAFETY; SYMPATHECTOMY;

EID: 84949634826     PISSN: None     EISSN: 11787104     Source Type: Book Series    
DOI: 10.2147/IBPC.S65632     Document Type: Review

References (114)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-223.
3. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114(11):1804-1814.
4. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976-990.
5. Patel H, di Mario C. Renal denervation for hypertension: where are we now? Br J Cardiol. 2013;20:142-147.
6. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-917.
7. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903-1909.
8. Patel HC, Hayward C, Di Mario C. SYMPLICITY HTN 3: the death knell for renal denervation in hypertension? Glob Cardiol Sci Pract. 2014;2014(1):94-98.
9. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370(15):1393-1401.
10. DiBona GF. Sympathetic nervous system and hypertension. Hypertension. 2013;61(3):556-560.
11. Del Colle S, Morello F, Rabbia F, et al. Antihypertensive drugs and the sympathetic nervous system. J Cardiovasc Pharmacol. 2007;50(5): 487-496.
12. Patel HC, Rosen SD, Lindsay A, Hayward C, Lyon AR, di Mario C. Targeting the autonomic nervous system: measuring autonomic function and novel devices for heart failure management. Int J Cardiol. 2013; 170(2):107-117.
13. Esler M, Jennings G, Biviano B, Lambert G, Hasking G. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol. 1986;8(Suppl 5):S39-S43.
14. Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension. 1998;31(1):64-67.
15. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R245-R253.
16. Winternitz SR, Oparil S. Importance of the renal nerves in the patho­genesis of experimental hypertension. Hypertension. 1982;4(5 Pt 2):III108-III114.
17. DiBona GF. Neural control of the kidney: functionally specific renal sympathetic nerve fibers. Am J Physiol Regul Integr Comp Physiol. 2000;279(5):R1517-R1524.
18. Sakakura K, Tunev S, Yahagi K, et al. Comparison of histopatho­logic analysis following renal sympathetic denervation over mul­tiple time points. Circ Cardiovasc Interv. 2015;8(2):doi:10.1161/circinterventions.1114.001813.
19. Katholi RE, Rocha-Singh KJ, Goswami NJ, Sobotka PA. Renal nerves in the maintenance of hypertension: a potential therapeutic target. Curr Hypertens Rep. 2010;12(3):196-204.
20. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympa­thetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275-1281.
21. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71(3):659-682.
22. Sobotka PA, Krum H, Bohm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep. 2012;14(3):285-292.
23. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106(15):1974-1979.
24. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932-934.
25. Peet MM. Hypertension and its surgical treatment by bilateral supra­diaphragmatic splanchnicectomy. Am J Surg. 1948;75(1):48-68.
26. Smithwick R. Surgical treatment of hypertension: the effect of radi­cal (lumbodorsal) splanchnicectomy on the hypertensive state of one hundred and fifty-six patients followed one to five years. Arch Surg. 1944;49(3):180-193.
27. Gazdar AF, Dammin GJ. Neural degeneration and regeneration in human renal transplants. N Engl J Med. 1970;283(5):222-224.
28. Hansen JM, Abildgaard U, Fogh-Andersen N, et al. The transplanted human kidney does not achieve functional reinnervation. Clin Sci (Lond). 1994;87(1):13-20.
29. Booth LC, Nishi EE, Yao ST, et al. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension. 2015;65(2):393-400.
30. Kline RL, Mercer PF. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am J Physiol. 1980;238(5):R353-R358.
31. Sankari B, Stowe N, Gavin JP, Satoh S, Nally JV, Novick AC. Studies on the afferent and efferent renal nerves following autotransplantation of the canine kidney. J Urol. 1992;148(1):206-210.
32. Getts RT, Hazlett SM, Sharma SB, et al. Regression of left ventricular hypertrophy after bilateral nephrectomy. Nephrol Dial Transplant. 2006;21(4):1089-1091.
33. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125(13):1635-1642.
34. Patel H, Hayward C, de Silva R. An approach to diagnosis and manage­ment of resistant hypertension. J Pract Cardiovasc Sci. 2015;1(1):60.
35. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence and prognosis. Circulation. 2012;125(13):1594-1596.
36. Patel HC, Hayward C, Ozdemir BA, et al. Magnitude of blood pres­sure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation. Hypertension. 2014;65(2):401-406.
37. Atherton DS, Deep NL, Mendelsohn FO. Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study. Clin Anat. 2012;25(5):628-633.
38. Sakakura K, Ladich E, Cheng Q, et al. Anatomic assessment of sym­pathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014; 64(7):635-643.
39. Patel H, Dhillon P, Mahfoud F, et al. The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol. 2014;103(5):337-344.
40. Henegar JR, Zhang Y, Hata C, Narciso I, Hall ME, Hall JE. Catheter-based radiofrequency renal denervation: location effects on renal norepinephrine. Am J Hypertens. 2015;28(7):909-914.
41. Patel HC, Otero S, Moser JB, et al. A cross-sectional imaging study to identify organs at risk of thermal injury during renal artery sympathetic denervation. Int J Cardiol. 2015;197:235-240.
42. Henegar JR, Zhang Y, De Rama R, Hata C, Hall ME, Hall JE. Catheter-based radiorefrequency renal denervation lowers blood pressure in obese hypertensive dogs. Am J Hypertens. 2014;27(10):1285-1292.
43. Vink EE, Goldschmeding R, Vink A, Weggemans C, Bleijs RL, Blankestijn PJ. Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study. Nephrol Dial Transplant. 2014;29(8):1608-1610.
44. Sakakura K, Ladich E, Edelman ER, et al. Methodological standardiza­tion for the pre-clinical evaluation of renal sympathetic denervation. JACC Cardiovasc Interv. 2014;7(10):1184-1193.
45. Chinushi M, Izumi D, Iijima K, et al. Blood pressure and autonomic responses to electrical stimulation of the renal arterial nerves before and after ablation of the renal artery. Hypertension. 2013;61(2):450-456.
46. Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622-629.
47. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart. 2013;99(21):1579-1587.
48. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
49. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambula­tory blood pressure monitoring. Hypertension. 2011;57(5):898-902.
50. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128(2):132-140.
51. Howard JP, Cole GD, Sievert H, et al. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. Int J Cardiol. 2014;172(1):29-35.
52. Howard JP, Patel H, Shun-Shin MJ, et al. Impact of number of pre­scribed medications on visit-to-visit variability of blood pressure: implications for design of future trials of renal denervation. J Hypertens. 2015;33(11):2359-2367.
53. Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4): 219-227.
54. Desch S, Okon T, Heinemann D, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015;65(6):1202-1208.
55. Rosa J, Widimsky P, Tousek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolac­tone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65(2):407-413.
56. Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care stan­dardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957-1965.
57. Kario K, Ogawa H, Okumura K, et al. SYMPLICITY HTN-Japan - first randomized controlled trial of catheter-based renal denervation in Asian patients. Circ J. 2015;79(6):1222-1229.
58. Pokushalov E, Romanov A, Corbucci G, et al. A randomized com­parison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60(13): 1163-1170.
59. Staessen JA, Jin Y, Thijs L, Persu A, Azizi M, Kjeldsen S. First-in-man randomized clinical trial of renal denervation for atrial arrhythmia raises concern. J Am Coll Cardiol. 2013;62(21):e445-e446.
60. Gal P, de Jong MR, Smit JJ, Adiyaman A, Staessen JA, Elvan A. Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study. J Hum Hypertens. 2015;29(5):292-295.
61. Fadl Elmula FEM, Jin Y, Yang WY, et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press. 2015;24(5):263-274.
62. Karanasos A, Van Mieghem N, Bergmann MW, et al. Multimodality intra-arterial imaging assessment of the vascular trauma induced by balloon-based and nonballoon-based renal denervation systems. Circ Cardiovasc Interv. 2015;8(7):e002474.
63. Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl. 2003;21(2):S37-S42.
64. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766-774.
65. Navar LG. Counterpoint: activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension. J Appl Physiol (1985). 2010;109(6):1998-2000; discussion 2015.
66. Vink EE, Verloop WL, Siddiqi L, van Schelven LJ, Liam Oey P, Blankestijn PJ. The effect of percutaneous renal denervation on muscle sympathetic nerve activity in hypertensive patients. Int J Cardiol. 2014; 176(1):8-12.
67. Hering D, Marusic P, Walton AS, et al. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension. 2014;64(1):118-124.
68. Ahmed H, Neuzil P, Skoda J, et al. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the man­agement of drug-resistant hypertension. JACC Cardiovasc Interv. 2012;5(7):758-765.
69. Bartus K, Sadowski J, Kapelak B, et al. Denervation of nerve terminals in renal arteries: one-year follow-up of interventional treatment of arte­rial hypertension. Kardiol Pol. 2014;72(5):425-431.
70. Bakris GL, Townsend RR, Flack JM, et al. 12-month blood pres­sure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314-1321.
71. Bausback Y, Friedenberger J, Hertting K, et al. Renal denervation for hypertension refractory to renal artery stenting. J Endovasc Ther. 2014;21(2):181-190.
72. Böhm M, Mahfoud F, Ukena C, et al. First report of the Global SYM­PLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015;65(4):766-774.
73. Brinkmann J, Heusser K, Schmidt BM, et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension. 2012;60(6):1485-1490.
74. Courand PY, Dauphin R, Rouvière O, et al. [Renal denervation for treating hypertension: experience at the University Hospital in Lyon]. Ann Cardiol Angeiol (Paris). 2014;63(3):183-188. French.
75. Damascelli B, Patelli G, Tichá V, et al. Catheter-based radiofrequency renal sympathetic denervation for resistant hypertension. J Vasc Interv Radiol. 2013;24(5):632-639.
76. Dong H, Jiang X, Liang T, et al. Transradial renal denervation for the treatment of resistant hypertension. J Invasive Cardiol. 2014;26(7):322-327.
77. Dong H, Jiang X, Liang T, et al. One-year outcomes of percutaneous renal denervation for the treatment of resistant hypertension: the first Chinese experience. Chin Med J (Engl). 2014;127(6):1003-1007.
78. Dorr O, Liebetrau C, Mollmann H, et al. Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive mark­ers for blood pressure reduction after renal sympathetic denervation. Hypertension. 2014;63(5):984-990.
79. Ewen S, Ukena C, Linz D, et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hyper­tension. Hypertension. 2015;65(1):193-199.
80. Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62(3):526-532.
81. Hart EC, McBryde FD, Burchell AE, et al. Translational examination of changes in baroreflex function after renal denervation in hypertensive rats and humans. Hypertension. 2013;62(3):533-541.
82. Honton B, Pathak A, Sauguet A, Fajadet J. First report of transradial renal denervation with the dedicated radiofrequency Iberis™ catheter. EuroIntervention. 2014;9(12):1385-1388.
83. Id D, Kaltenbach B, Bertog SC, et al. Does the presence of accessory renal arteries affect the efficacy of renal denervation? JACC Cardiovasc Interv. 2013;6(10):1085-1091.
84. Kaiser L, Beister T, Wiese A, et al. Results of the ALSTER BP real-world registry on renal denervation employing the Symplicity system. EuroIntervention. 2014;10(1):157-165.
85. Kiuchi MG, Maia GL, de Queiroz Carreira MA, et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J. 2013;34(28):2114-2121.
86. Korovesis S, Giazitzoglou E, Pantos I, et al. Renal denervation for resistant hypertension: acute results and long-term follow-up. Hellenic J Cardiol. 2014;55(3):211-216.
87. Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denerva­tion in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622-629.
88. Lambert T, Nahler A, Reiter C, et al. Influence of pseudo-resistance on the effect of renal denervation on 24-hour ambulatory blood pressure levels. Catheter Cardiovasc Interv. 2015;86(3):126-130.
89. Luetkens JA, Wilhelm K, Düsing R, et al. Renal denervation: results of a single-center cohort study. Rofo. 2015;187(1):36-41.
90. Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention. 2012;8(1):57-61.
91. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128(2):132-140.
92. Ormiston JA, Watson T, van Pelt N, et al. Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial. EuroIntervention. 2013;9(1):70-74.
93. Ott C, Janka R, Schmid A, et al. Vascular and renal hemody­namic changes after renal denervation. Clin J Am Soc Nephrol. 2013;8(7):1195-1201.
94. Ott C, Mahfoud F, Schmid A, et al. Improvement of albuminuria after renal denervation. Int J Cardiol. 2014;173(2):311-315.
95. Ott C, Mahfoud F, Schmid A, et al. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62(20):1880-1886.
96. Persu A, Jin Y, Azizi M, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28(3):150-156.
97. Prochnau D, Heymel S, Gobel B, Figulla HR, Surber R. Resistant hypertension: multivariate predictors of blood pressure response to renal denervation. Int J Cardiol. 2013;168(3):3130-3132.
98. Schlaich MP, Bart B, Hering D, et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013;168(3):2214-2220.
99. Scheurig-Muenkler C, Weiss W, Foert E, et al. Renal denervation for refractory hypertension—technical aspects, complications and radia­tion exposure. Rofo. 2013;185(6):550-557.
100. Schwerg M, Heupel C, Strajnic D, et al. Renal sympathetic denervation: early impact on ambulatory resistant hypertension. J Clin Hypertens (Greenwich). 2014;16(6):406-411.
101. Templin C, Jaguszewski M, Ghadri JR, et al. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity catheter system and the EnligHTN multi-electrode renal denervation catheter. Eur Heart J. 2013;34(28):2141-2148, 2148b.
102. Tuohy ST, Kyvelou SG, Gleeson PJ, et al. The effect of renal sym­pathetic denervation on nocturnal dipping in patients with resistant hypertension; observational data from a tertiary referral centre in the Republic of Ireland. Ir J Med Sci. Epub 2015 Jun 19.
103. Vase H, Mathiassen ON, Kaltoft A, et al. Catheter-based renal denervation for treatment of resistant hypertension. Dan Med J. 2012;59(6):A4439.
104. Verloop WL, Vink EE, Spiering W, et al. Renal denervation in multiple renal arteries. Eur J Clin Invest. 2014;44(8):728-735.
105. Versaci F, Trivisonno A, Olivieri C, Caranci F, Brunese L, Prati F. Vascular response after percutaneous sympathectomy: not all devices are equal. Int J Cardiol. 2014;174(2):406-407.
106. Vogel B, Kirchberger M, Zeier M, et al. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol. 2014;103(2):117-124.
107. Volz S, Andersson B, Manhem K, Haraldsson I, Rundqvist B. Effect of catheter-based renal sympathetic denervation on 24-h ambulatory blood pressure in patients with resistant hypertension. Blood Pressure. 2014;23(4):228-232.
108. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympa­thetic denervation on blood pressure, sleep apnea course, and glyce­mic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58(4):559-565.
109. Worthley SG, Tsioufis CP, Worthley MI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hyper­tension: the EnligHTN I trial. Eur Heart J. 2013;34(28):2132-2140.
110. Ewen S, Mahfoud F, Linz D, et al. Effects of renal sympathetic dener­vation on exercise blood pressure, heart rate, and capacity in patients with resistant hypertension. Hypertension. 2014;63(4):839-845.
111. Hering D, Lambert EA, Marusic P, et al. Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hyper­tens. 2013;31(9):1893-1900.
112. Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60(2):419-424.
113. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympa­thetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123(18):1940-1946.
114. Zhang ZH, Yang K, Jiang FL, Zeng LX, Jiang WH, Wang XY. The effects of catheter-based radiofrequency renal denervation on renal function and renal artery structure in patients with resistant hyperten­sion. J Clin Hypertens (Greenwich). 2014;16(8):599-605.